Login / Signup

Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors.

Noritoshi KobayashiShoko TakanoKenichi ItoMadoka SugiuraMatsuyoshi OgawaYuma TakedaNaoki OkuboAkihiro SuzukiMotohiko TokuhisaTomohiro KanetaDaisuke UtsunomiyaMasaharu HataTomio InoueMakoto HosonoSeigo KinuyaYasushi Ichikawa
Published in: Annals of nuclear medicine (2021)
PRRT with 177Lu-DOTATATE was well-tolerated and showed good outcomes in Japanese patients with unresectable NETs. Peptide receptor radionuclide therapy, 177Lu-DOTA0-Tyr3-octreotate .
Keyphrases
  • neuroendocrine tumors
  • pet ct
  • amino acid
  • multiple sclerosis
  • low dose
  • squamous cell carcinoma
  • type diabetes
  • radiation therapy
  • metabolic syndrome
  • skeletal muscle
  • mesenchymal stem cells
  • locally advanced